Subject: PR tied to their Japan partner
Otsuka, the Japan partner, took the expected next step of submitting the drug so they can start selling in 2025. This is expected to trigger a $20m milestone payment to Esperion, presumably here in Q4.

While expected, it is good to see things moving forward.

https://www.esperion.com/news-...

Dreamer